GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,559.00GBp
8:15am EDT
Change (% chg)

-25.50p (-1.61%)
Prev Close
1,584.50p
Open
1,594.00p
Day's High
1,594.00p
Day's Low
1,557.00p
Volume
2,769,934
Avg. Vol
8,693,841
52-wk High
1,689.00p
52-wk Low
1,296.50p

GSK.L

Chart for GSK.L

About

GlaxoSmithKline plc. (GSK) is a healthcare company. GSK develops pharmaceutical, vaccine and consumer healthcare products. The pharmaceuticals business develops and makes medicines to treat a range of acute and chronic diseases. The vaccines business produces paediatric and adult vaccines against a range of infectious diseases.... (more)

Overall

Beta: 0.51
Market Cap(Mil.): £77,083.34
Shares Outstanding(Mil.): 4,864.84
Dividend: 23.00
Yield (%): 5.05

Financials

  GSK.L Industry Sector
P/E (TTM): 27.87 40.31 40.78
EPS (TTM): 0.57 -- --
ROI: 10.43 16.86 16.19
ROE: 48.95 17.40 17.04
Search Stocks

J&J, Glaxo settle U.S. lawsuit over allergy ads

NEW YORK - GlaxoSmithKline Plc has agreed to settle a lawsuit by Johnson & Johnson accusing it of using false advertising at the start of the U.S. allergy season to grab market share.

30 Mar 2015

J&J, Glaxo settle U.S. lawsuit over allergy ads

NEW YORK - GlaxoSmithKline Plc has agreed to settle a lawsuit by Johnson & Johnson accusing it of using false advertising at the start of the U.S. allergy season to grab market share.

30 Mar 2015

J&J, Glaxo settle U.S. lawsuit over allergy ads

NEW YORK, March 30 - GlaxoSmithKline Plc has agreed to settle a lawsuit by Johnson & Johnson accusing it of using false advertising at the start of the U.S. allergy season to grab market share.

30 Mar 2015

GSK agrees UK deal for meningitis shot after Novartis stand-off

LONDON - GlaxoSmithKline has reached a deal with the British government to supply a new meningitis B vaccine, following a lengthy stand-off over price with the product's previous owner Novartis.

29 Mar 2015

GSK agrees UK deal for meningitis shot after Novartis stand-off

LONDON, March 29 - GlaxoSmithKline has reached a deal with the British government to supply a new meningitis B vaccine, following a lengthy stand-off over price with the product's previous owner Novartis.

29 Mar 2015

BRIEF-GSK receives approval for Encruse Ellipta in Japan

* Press release - GSK receives approval for Encruse Ellipta (umeclidinium) in Japan for the treatment of COPD

26 Mar 2015

UPDATE 2-FDA panel backs Glaxo asthma drug for adults, not adolescents

March 19 - GlaxoSmithKline Plc's drug to treat chronic breathing problems is safe and effective enough for adults with asthma to use but not adolescents, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday.

19 Mar 2015

FDA staff finds no new safety problems with Glaxo's asthma drug

- GlaxoSmithKline Plc's respiratory treatment for chronic breathing problems did not show any new safety problems while being tested to treat asthma, a preliminary review by U.S. Food and Drug Administration staff found.

17 Mar 2015

UPDATE 2-FDA staff finds no new safety problems with Glaxo's asthma drug

March 17 - GlaxoSmithKline Plc's respiratory treatment for chronic breathing problems did not show any new safety problems while being tested to treat asthma, a preliminary review by U.S. Food and Drug Administration staff found.

17 Mar 2015

BRIEF-GSK announces start of phase III programme to evaluate retosiban

* GSK announces start of phase III programme to evaluate retosiban for spontaneous preterm labour

17 Mar 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: ValuEngine, Inc.
$49.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks